Overview

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

Status:
Completed
Trial end date:
2017-03-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Adalimumab
Methotrexate